Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.69 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | GSR | P00390 | 2/20 | 0.49 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.47 |
| ▸ | GRM6 | O15303 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7563962 | 1.00 | FOLH1 (0.69) | FOLH1DPP8DPP9DPP4GSR | |
| SCHEMBL21330535 | 1.00 | FOLH1 (0.69) | FOLH1DPP8DPP9DPP4GSR | |
| SCHEMBL397256 | 1.00 | FOLH1 (0.69) | FOLH1DPP8DPP9DPP4GSR | |
| SCHEMBL29371650 | 1.00 | FOLH1 (0.69) | FOLH1DPP8DPP9DPP4GSR | |
| SCHEMBL30394354 | 0.97 | FOLH1 (0.66) | FOLH1DPP8DPP9DPP4GSR | |
| SCHEMBL29617541 | 0.96 | FOLH1 (0.68) | FOLH1DPP8DPP9DPP4GSR | |
| SCHEMBL31665998 | 0.96 | FOLH1 (0.68) | FOLH1DPP8DPP9DPP4GSR | |
| SCHEMBL29988016 | 0.96 | FOLH1 (0.68) | FOLH1DPP8DPP9DPP4GSR | |
| SCHEMBL29534230 | 0.96 | FOLH1 (0.68) | FOLH1DPP8DPP9DPP4GSR | |
| SCHEMBL30468678 | 0.96 | FOLH1 (0.68) | FOLH1DPP8DPP9DPP4GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 676 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747264-A1 | MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE | University of Reading (GB) | 2026-05-27 | — | — | EP | claimed |
| US-20250326814-A1 | MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOF | OPKO BIOLOGICS LTD. (IL) | 2025-10-23 | — | — | US | claimed |
| EP-4623143-A1 | METHOD FOR PRODUCING REINFORCED TEXTILE FIBER COMPOSITIONS | LigaMore ApS (DK) | 2025-10-01 | — | — | EP | claimed |
| WO-2025051774-A1 | PLANT-BASED FOOD PRODUCT AND METHOD FOR PRODUCING THE SAME | PLANTED FOODS AG (CH) | 2025-03-13 | — | — | WO | claimed |
| WO-2025037123-A1 | MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE | UNIVERSITY OF READING (GB) | 2025-02-20 | — | — | WO | claimed |
| CN-119301141-A | Compound of double-targeting tumor cells, preparation method and application thereof | 中国医学科学院北京协和医院 | 2025-01-10 | — | — | CN | claimed |
| US-20240382630-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES UK LIMITED (GB) | 2024-11-21 | — | — | US | claimed |
| EP-4433516-A1 | METHOD FOR THE TREATMENT OF A SCLERODERMA DISEASE | UCB Biopharma SRL (BE) | 2024-09-25 | — | — | EP | claimed |
| EP-4426727-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | claimed |
| EP-4426729-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | claimed |
| EP-2776832-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| US-8608922-B2 | Biosensor for continuous monitoring of metabolites and proteins and methods of manufacture thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2013-12-17 | — | — | US | claimed |
| WO-2013070839-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-20100116691-A1 | BIOSENSOR FOR CONTINUOUS MONITORING OF METABOLITES AND PROTEINS AND METHODS OF MANUFACTURE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2010-05-13 | — | — | US | claimed |
| US-7312090-B2 | Label-free methods for performing assays using a colorimetric resonant reflectance optical biosensor | SRU BIOSYSTEMS, INC. (US) | 2007-12-25 | — | — | US | claimed |
| US-7153702-B2 | Label-free methods for performing assays using a colorimetric resonant reflectance optical biosensor | SRU BIOSYSTEMS, INC. (US) | 2006-12-26 | — | — | US | claimed |
| US-20060281077-A1 | Label-free methods for performing assays using a colorimetric resonant reflectance optical biosensor | SRU BIOSYSTEMS, INC. | 2006-12-14 | — | — | US | claimed |
| US-20030068657-A1 | Label-free methods for performing assays using a colorimetric resonant reflectance optical biosensor | SRU BIOSYSTEMS LLC (US) | 2003-04-10 | — | — | US | claimed |
| US-6008256-A | COMPRISES (A) LIDOCAINE, (B) EPINEPHRINE IN SPECIFIC AMOUNT, AND (C) ONE OR MORE AMINO ACIDS; EXCELLENT STORAGE STABILITY | SHOWA YAKUHIN KAKO CO., LTD. (JP) | 1999-12-28 | — | — | US | claimed |
| EP-0858803-A1 | COMPOSITION FOR LOCAL ANESTHESIA | Showa Yakuhin Kako Co. Ltd (JP) | 1998-08-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382630-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | ASGR1, GNRHR, SCTR | FOLH1 22/4885DPP8 456/4885DPP9 548/4885 |
| US-20250326814-A1 | MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOF | OGFRL1, OXGR1, THOP1 | FOLH1 1679/4885DPP8 971/4885DPP9 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.